secwatch.observer — SEC 8-K summary
======================================

Issuer:     Finch Therapeutics Group, Inc. (FNCHQ)
CIK:        0001733257
Form:       8-K
Filed at:   2021-10-05T23:59:59+00:00
Accession:  0001193125-21-291534
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Finch Therapeutics appoints Samuel Allen Hamood to Board of Directors
---------------------------------------------------------------------

- Hamood elected as Class I director effective Oct 1, 2021; also chairs new Finance Committee.
- Annual cash retainers: $35,000 for Board, $5,000 for Finance Committee, $10,000 as chair.
- Initial equity grant: option to buy 25,543 shares at $12.94, $200,000 fair value, 3-year vest.
- Hamood serves as President and CAFO of Culligan International; 30+ years of finance experience.
- Board determined Hamood qualifies as independent under SEC and Nasdaq standards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733257/000119312521291534/0001193125-21-291534-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733257/000119312521291534/d222985d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-291534

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer